ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014
Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.
Registry-linked trialAbstract readMulticenter Study
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03992352 (Composite Health Assessment Risk Model), which is not on this map. Cited by 189 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
189citing papers in PubMed, 4 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Composite Health Assessment Risk Model (CHARM) for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and BioMarkers on Non-Relapse Mortality After Allogeneic Transplant (BMT CTN 1704)
Who cites it
189 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- A comparative analysis of hematopoietic stem cell transplantation in pediatric and adult patients: a systematic review and meta-analysis.Frontiers in transplantation · 2025Pooled it
- The NICE COVID-19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact.British journal of haematology · 2021Guideline
- Guideline
- Pooled it
- Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.The New England journal of medicine · 2025Trial
- Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation.Blood advances · 2025Trial
- A novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction.Blood cancer journal · 2021Trial
- A randomized double-blind placebo-controlled trial of intravenous thiamine for prevention of delirium following allogeneic hematopoietic stem cell transplantation.Journal of psychosomatic research · 2021Trial
- Trial
- Presalvage International Staging System Stage and Other Important Outcome Associations in CD34Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Trial
- Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting.Bone marrow transplantation · 2018Trial
- Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.Bone marrow transplantation · 2017Trial
- Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI.Haematologica · 2016Trial
- FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.Bone marrow transplantation · 2016Trial
- Developing a Risk Prediction Model for Long-Term Physical and Psychological Functioning after Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Trial
- Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Trial
- Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation.Bone marrow transplantation · 2015Trial
- Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation.British journal of haematology · 2015Trial
- Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Trial
- Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Trial
129 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Mohamed L SorrorMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO. msorror@fhcrc.org.
Rainer F StorbMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO.
Brenda M SandmaierMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO.
Richard T MaziarzMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO.
Michael A PulsipherMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO.
Michael B MarisMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO.
Smita BhatiaMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO.
Fabiana OstronoffMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO.
H Joachim DeegMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO.
Karen L SyrjalaMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO.
Elihu EsteyMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO.
David G MaloneyMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO.
Frederick R AppelbaumMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO.
Paul J MartinMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO.
Barry E StorerMohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, Paul J. Martin, and Barry E. Storer, Fred Hutchinson Cancer Research Center; Mohamed L. Sorror, Rainer F. Storb, Brenda M. Sandmaier, Fabiana Ostronoff, H. Joachim Deeg, Karen L. Syrjala, Elihu Estey, David G. Maloney, Frederick R. Appelbaum, and Paul J. Martin, University of Washington School of Medicine; Barry E. Storer, University of Washington School of Public Health, Seattle, WA; Smita Bhatia, City of Hope School of Medicine, Duarte, CA; Richard T. Maziarz, Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute and School of Medicine, Portland, OR; Michael A. Pulsipher, University of Utah School of Medicine and Primary Children's Medical Center, Huntsman Cancer Institute, Salt Lake City, UT; and Michael B. Maris, Colorado Blood Cancer Institute School of Medicine, Denver, CO.
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4MVIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Ted A Gooley · 1985 to 2026
$128.4MProject 3: Stem Cell Allografts for Lymphoid MalignanciesP01CA078902 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SANDMAIER, BRENDA MARIE · 1999 to 2025
$46.1MUNRELATED AND HLA-MISMATCHED RELATED DONOR TRANSPLANTSP01HL036444 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RAWLINGS, DAVID J · 1986 to 2010
$25.9MInternet Studies to Enhance Long Term Survivorship after Hematologic MalignancyR01CA160684 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SYRJALA, KAREN LESLIE · 2011 to 2015
$3.4MImpact of Comorbidities on Outcomes of Allogeneic TransplantationR00HL088021 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SORROR, MOHAMED · 2011 to 2013
$735kImpact of Comorbidities on Outcomes of Allogeneic TransplantationK99HL088021 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SORROR, MOHAMED · 2007 to 2008
$178kNCI NIH HHS CA018029NCI NIH HHS CA078902NCI NIH HHS P01 CA018029NCI NIH HHS P01 CA078902NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA160684NHLBI NIH HHS HL036444NHLBI NIH HHS HL088021NHLBI NIH HHS K99 HL088021NHLBI NIH HHS P01 HL036444NHLBI NIH HHS R00 HL088021
Abstract
purposeAge has long been used as a major factor for assessing suitability for allogeneic hematopoietic cell transplantation (HCT). The HCT-comorbidity index (HCT-CI) was developed as a measure of health status to predict mortality risk after HCT. Whether age, comorbidities, or both should guide decision making for HCT is unknown. PATIENTS AND
methodsData from 3,033 consecutive recipients of HLA-matched grafts from five institutions contributed to this analysis. Patients were randomly divided into a training set to develop weights for age intervals and a validation set to assess the performance of prognostic models.
resultsIn the training set, patients age 20 to 39 years, 40 to 49 years, 50 to 59 years, and ≥ 60 years had hazard ratios for nonrelapse mortality (NRM) of 1.21 (P = .29), 1.48 (P = .04), 1.75 (P = .004), and 1.84 (P = .005), respectively, compared with those age younger than 20 years. Consequently, age ≥ 40 years was assigned a weight of 1 to be added to the HCT-CI to constitute a composite comorbidity/age index. In the validation set, the composite comorbidity/age score had statistically significantly higher c-statistic estimates for prediction of NRM (0.664 v 0.556; P < .001) and survival (0.682 v 0.560; P < .001) compared with age, respectively. Patients with comorbidity/age scores of 0 to 2 had comparable mortality risks regardless of conditioning regimens. Patients with scores of 3 to 4 and ≥ 5 had statistically significant higher mortality risks after high-dose versus nonmyeloablative regimens.
conclusionAge is a poor prognostic factor. The proposed composite measure allows integration of both comorbidities and age into clinical decision making and comparative-effectiveness research of HCT.
Indexed as
Decision MakingHealth Status IndicatorsHematopoietic Stem Cell TransplantationAdultAgedAge FactorsComorbidityFemaleHematologic NeoplasmsHumansMaleMiddle AgedPrognosisRetrospective StudiesTransplantation, HomologousTreatment Outcome
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT03992352ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.